Danish national medicines regulator contributing pharmacovigilance expertise and medical device regulatory authority to EU health research consortia.
The Danish Medicines Agency (Lægemiddelstyrelsen) is Denmark's national regulatory authority responsible for approving and supervising medicines, medical devices, and clinical trials. In EU research projects, they contribute what no academic or industry partner can replicate: the authoritative perspective of a national competent authority, including access to national pharmacovigilance databases and medical device registries. Their H2020 participation spans two distinct regulatory domains — digital adverse drug reaction reporting (WEB-RADR 2) and the clinical evidence challenge posed by the EU Medical Devices Regulation (CORE-MD) — positioning them as bridge-builders between research outcomes and regulatory implementation. For consortium builders, their presence signals a direct line to Danish regulatory practice and strengthens the credibility of any research intended to influence EU-level policy or market access pathways.
CORE-MD (2021-2024) addressed the challenge of generating adequate clinical evidence for high-risk medical devices under the EU MDR, covering cardiology, orthopaedics, and diabetes device categories.
WEB-RADR 2 (2018-2020) focused on improving web-based and mobile reporting of adverse drug reactions, an IMI2-funded initiative to modernise EU pharmacovigilance infrastructure.
Both projects sit squarely within regulatory science — defining what counts as adequate evidence for regulatory decisions on drugs and devices.
CORE-MD explicitly covered device registry methodologies as a source of post-market clinical evidence for high-risk implants.
CORE-MD examined trial methodologies and clinical investigation designs specific to medical devices, distinct from pharmaceutical trial standards.
Their first H2020 engagement (WEB-RADR 2, 2018-2020) sat firmly in pharmaceutical safety — specifically modernising how adverse drug reactions are collected and processed through digital channels, a domain driven by EU pharmacovigilance legislation. By 2021, their focus shifted decisively toward medical devices: CORE-MD tackled the acute shortage of clinical evidence for high-risk devices triggered by the EU Medical Devices Regulation (MDR 2017/745), which came into force in 2021 and demanded far stricter clinical proof than predecessor legislation. This shift tracks a real regulatory crisis in Europe — thousands of legacy devices suddenly needed reclassification — and the Agency's involvement reflects their front-line role managing that transition in Denmark.
Their trajectory follows the EU regulatory reform agenda — from drug safety digitalisation toward the medical device evidence gap — suggesting future collaborations are most likely in EU MDR implementation, post-market surveillance, or registry-based real-world evidence for devices.
The Agency joins projects as a specialist participant, never as coordinator — a pattern typical of national regulatory authorities that contribute legitimacy and data access rather than project management capacity. Despite only two projects, they have accumulated 33 distinct consortium partners across 14 countries, which reflects the large multi-stakeholder consortia typical of IMI2 and CSA funding schemes rather than a broad independent network. Working with them means access to a national competent authority perspective, but expect them to play a focused advisory or data-access role rather than a work-package leadership one.
Despite only two projects, the Agency has worked with 33 unique partners across 14 countries — a network breadth explained by the large, pan-European consortia that IMI2 and CSA schemes typically require. Their connections are predominantly within the European health regulatory and clinical research ecosystem.
As a national competent authority, the Danish Medicines Agency brings something researchers and companies cannot: legal standing within the EU regulatory system and direct access to national adverse event reports and device registry data. Their participation in a consortium is a signal to other regulators and to the European Medicines Agency that the research agenda is grounded in real regulatory need. For any project aiming to produce outputs that influence EU regulatory guidance, device certification practice, or pharmacovigilance methodology, their involvement dramatically shortens the distance between research finding and regulatory uptake.
